ST葫芦娃：拟与关联方签署技术合作开发合同

Core Viewpoint - ST Huluwawa (605199) announced on October 17 that it plans to sign two technology cooperation development contracts with its affiliate Hangzhou Kanglixian Pharmaceutical Technology Co., Ltd. to jointly develop "Ondansetron Oral Soluble Film" and "Ibandronate Sodium Injection Concentrate Solution" projects, with a total estimated contract amount of 11.25 million yuan [1] Group 1 - The company intends to collaborate on two specific pharmaceutical projects [1] - The estimated contract amounts for the projects are 9.1 million yuan and 2.15 million yuan respectively [1] - The total estimated contract value for both projects is 11.25 million yuan [1]